When was NextBio founded?

NextBio was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Where is NextBio located?

NextBio is headquartered in Santa Clara, United States.

How many employees does NextBio have?

As of Mar 31, 2026, the latest employee count at NextBio is 28.

Is NextBio a funded company?

NextBio is a funded company, having raised a total of $28.3M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 11, 2005.

When was the latest funding round of NextBio?

NextBio's latest funding was a $***** Grant (prize money) round on Jul 01, 2010, with participation from 1 investor.

Where does NextBio rank among its competitors?

NextBio ranks 31st amongst 523 active competitors, of which 132 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Evotec, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of NextBio?

NextBio's top competitors include Evotec, Benchling and Helix. Among them, Evotec secured the most recent funding round in January, 2026.

NextBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

NextBio, a software company that provides a platform for life science researchers to search, discover and share knowledge across public and proprietary data. The NextBio Platform is an ontology-based semantic framework that connects highly heterogeneous data and textual information. The semantic framework is based on gene, tissue, disease and compound ontologies. The enterprise version of the NextBio platform is being used in life science R&D and drug development by researchers and clinicians at Pharma Companies. It has been acquired by Illumina.

Website: nextbio.com
Social

Key Metrics

Founded Year

2004

Location

Santa Clara, United States

Stage

Acqui-Hired

Total Funding

$28.3M in 10 rounds

Latest Funding Round

Grant (prize money), Jul 01, 2010, $*****

Investors

Rising Tide Fund & 7 more

Ranked

31^st among 523 active competitors

Employee Count

28 as on Mar 31, 2026

Similar Companies

Evotec & 697 more

View NextBio's full profile

NextBio has raised a total funding of $28.3M over 10 rounds. Its first funding round was on Feb 11, 2005. Its latest funding round was a Grant (prize money) round on Jul 01, 2010 for $*****. 1 investor participated in its latest round. NextBio has 8 institutional investors.

Here is the list of recent funding rounds of NextBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2010	9411900	Grant (prize money)	9512697	4329586	9763285	4980098
Sep 17, 2009	6031266	Series C	6556471	8562015	4484994	6083513
Jun 24, 2009	3796799	Series C	4347496	7067506	9312841	4616773

Access funding benchmarks and valuations. Sign up today!

View details of NextBio's funding rounds and investors

The founders of NextBio are Mostafa Ronaghi, Saeid Akhtari and Ilya Kupershmidt.

Here are the details of NextBio's key team members:

Mostafa Ronaghi: Former Co-Founder of NextBio and founder of 3 other companies, ParAllele BioScience, GRAIL and Cellanome. They are also an angel investor in 4 startups.
Saeid Akhtari: Co-Founder of NextBio and founder of 1 other company. They serve on the board of 1 company.
Ilya Kupershmidt: Co-Founder of NextBio.

View details of NextBio's Founder profiles and Board Members

NextBio's employee count trend

NextBio has 28 employees as of Mar 26. Here is NextBio's employee count trend over the years:

Uncover NextBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NextBio include Evotec, Benchling and Helix. Here is the list of Top 10 competitors of NextBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	TVM Capital Life Science, Omega Funds & 20 others	76/100
2nd	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Benchmark & 28 others	72/100
3rd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	Warburg Pincus, DFJ Growth & 12 others	71/100
4th	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	Autonomy Ventures, New Mountain Capital & 3 others	66/100
7th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Viola Group, Catalio Capital Management & 14 others	66/100
8th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
9th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$209M	Andreessen Horowitz, CPP Investments & 11 others	64/100
10th	NewLimit 2022, San Francisco (United States), Series B	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$247M	Kleiner Perkins, Lilly & 17 others	64/100
31st	NextBio 2004, Santa Clara (United States), Acqui-Hired	NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications.	$28.3M	Rising Tide Fund, RONA Holdings & 6 others	56/100